Radhakrishnan Laboratory
The research focus of the Radhakrishnan lab is to advance the field of cellular immunotherapy and is based on two divergent yet complimentary themes:
1) Development of CAR T cells targeting novel antigens for both solid and hematological cancers. The lab uses antibody phage display library and high throughput downstream assays to identify binding antibodies and functional CAR T cells. Using this platform, during his post-doctoral training at the University of Utah, Dr. Radhakrishnan has developed the first human CD229 antibody and CAR T cells and shown efficacy in multiple myeloma and B cell neoplasms.
2) Overcoming immunosuppressive tumor microenvironment to enhance CAR T cell therapy. The Radhakrishnan lab employs a multimodal approach to activate tumor macrophages using CAR T cells, thus enhancing their tumoricidal effect. In this regard the lab focuses on targeting the “do not eat me signal” CD47 and CD24 to enhance CAR T cell or tumor infiltrating lymphocytes in both solid and hematological cancers.
About the PI
Sabarinath Radhakrishnan, MD, is an Assistant Professor in the Division of Hematology & Oncology at the Medical College of Wisconsin. He obtained his medical degree (MBBS) and post graduate degree (MD) from Trivandrum Medical College, Kerala, India and further completed Internal Medicine residency at LSU Shreveport and Hematology/Oncology fellowship at the University of Utah. His initial research focus was on graft versus host disease and trained under the mentorship of Gerhard Hildebrandt MD at LSU Shreveport. During his fellowship at the University of Utah, under the guidance of Tim Luetkens, MD and Djordje Atanackovic, MD, he developed a high throughput CAR T cell discovery platform using phage display technology and successfully generated the first CD229 targeting CAR T cells.
Dr. Radhakrishnan joined MCW in 2021 and attends to the bone marrow transplant and cellular therapy service at Froedtert Hospital and his lab is focused on developing CAR T cells against novel targets and overcoming CAR T cell resistance.
Current Members
Maday Galeana Figueroa
Research Associate I
Kishan Nyati, PhD
Postdoctoral Fellow
Tarang Sharma, PhD
Postdoctoral Fellow
Recent Publications
-
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma.
(Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P.) Blood Adv. 2022 Apr 26;6(8):2466-2470 PMID: 34933344 PMCID: PMC9043928 SCOPUS ID: 2-s2.0-85129331026 12/22/2021
-
(Palaniyandi S, Kumari R, Venniyil Radhakrishnan S, Strattan E, Hakim N, Munker R, Kesler MV, Hildebrandt GC.) Transplantation. 2020 Dec;104(12):2507-2515 PMID: 32639407 PMCID: PMC8139022 SCOPUS ID: 2-s2.0-85096509107 07/09/2020
-
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.
(Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER, Olson ML, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic D.) Nat Commun. 2020 Feb 07;11(1):798 PMID: 32034142 PMCID: PMC7005855 SCOPUS ID: 2-s2.0-85079080842 02/09/2020
-
(Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T.) Leukemia. 2020 Jan;34(1):317-321 PMID: 31409922 SCOPUS ID: 2-s2.0-85070798814 08/15/2019
-
A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma.
(Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot G.) Cell Transplant. 2019 Dec;28(12):1624-1631 PMID: 31619057 PMCID: PMC6923548 SCOPUS ID: 2-s2.0-85076876281 10/18/2019
-
The role of surface molecule CD229 in Multiple Myeloma.
(Olson M, Radhakrishnan SV, Luetkens T, Atanackovic D.) Clin Immunol. 2019 Jul;204:69-73 PMID: 30326256 SCOPUS ID: 2-s2.0-85055712528 10/17/2018
-
Elotuzumab as a novel anti-myeloma immunotherapy.
(Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D.) Hum Vaccin Immunother. 2017 Aug 03;13(8):1751-1757 PMID: 28604269 PMCID: PMC5557243 SCOPUS ID: 2-s2.0-85020548304 06/13/2017
-
(Templin J, Atanackovic D, Hasche D, Radhakrishnan SV, Luetkens T.) Oncotarget. 2017 Jul 25;8(30):49253-49263 PMID: 28512269 PMCID: PMC5564765 SCOPUS ID: 2-s2.0-85025814243 05/18/2017
-
Current Strategies for the Immunotherapy of Multiple Myeloma.
(Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D.) Oncology (Williston Park). 2017 Jan 15;31(1):55-63 PMID: 28090624 SCOPUS ID: 2-s2.0-85050440905 01/17/2017
-
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.
(Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D.) Oncoimmunology. 2017;6(5):e1308618 PMID: 28638731 PMCID: PMC5468000 SCOPUS ID: 2-s2.0-85019019970 06/24/2017
-
Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
(Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T.) Br J Haematol. 2016 Mar;172(5):685-98 PMID: 26791002 SCOPUS ID: 2-s2.0-84958899793 01/23/2016
-
Immunotherapies targeting CD38 in Multiple Myeloma.
(Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T.) Oncoimmunology. 2016;5(11):e1217374 PMID: 27999737 PMCID: PMC5139636 12/22/2016